Nanologica AB (publ), a life science tools company, develops, manufactures, and sells nanoporous silica particles in China, India, Turkey, the United States, and internationally. The company offers NLAB Saga, a silica-based purification media for preparative chromatography that is developed for the purification of peptide drugs, such as insulin and GLP-1 analogues; NLAB Idun, an ion exchange product for robust, reproducible, and efficient downstream purification of GLP-1 analogues and other peptides; NLAB Idun SP, a strong cation exchanger with sulfopropyl groups as ligands; NLAB Idun Q, a strong anion exchanger with a quaternary amine ligand; and NLAB Siv, a non-silica-based media for purification by preparative chromatography used for products outside the peptide range. It also provides high-performance liquid chromatography, a separation method based on different substances in a solution passing through a column at different paces; and analytical chromatography, an analysis method in the pharmaceutical and food industries. The company's products are used to purify substances with a focus on peptide drugs for the treatment of diabetes and obesity. It serves pharmaceutical companies, as well as contract manufactures of insulin and insulin analogues, GLP-1 analogues, biosimilars to insulin and GLP-1 analogues, and other peptide drugs. Nanologica AB (publ) was incorporated in 2004 and is headquartered in Södertälje, Sweden.…
AstraZeneca strikes again, BioArctic's Leqembi goes global and Cinclus holds its breath – the Nordic Pulse | 2026:36
Nanologica (STO: NICA) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 72 employees.
The shares were at 0.1645 SEK on 20 November 2026, down 85.4% over 52 weeks. Its 52-week range is 0.1565 SEK to 2.250 SEK: the price is 92.7% below the high and 5.1% above the low.
Its market capitalisation is 54.08M SEK.
Nanologica reports return on equity of -226.5%, an operating margin of 12.3% and revenue up 931.1% year over year.
Its debt exceeds its cash by 34.57M SEK, a debt-to-equity ratio of 0.95. Its Piotroski F-score is 5 out of 9, an average reading of its financial health.